Johnson & Johnson

Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.Anna Moneymaker | Getty ImagesA federal judge on Monday dismissed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations that challenged Medicare's new powers to negotiate prices for costly prescription medicines. The decision is an early win for the Biden administration as it grapples with a flurry of other legal…

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Bill Clark | Cq-roll Call, Inc. | Getty ImagesSenators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. The push to cut drug prices is one of those rare hot-button…

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.It took subpoena…

The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSEBig pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.That refers to when a company's patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of those drugs, often at a lower…

US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People's Action, protesting pharmaceutical companies' lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021.Saul Loeb | AFP | Getty ImagesThe CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders…

Containers of Johnson and Johnson baby powder are displayed on a Walgreens shelf on April 05, 2023 in San Anselmo, California.Justin Sullivan | Getty ImagesJohnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into whether the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which…

The stock trading graph of Johnson & Johnson is seen on a smartphone screen.Rafael Henrique | SOPA Images | LightRocket | Getty ImagesJohnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged.J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. Here's what J&J …

Medical personnel use a mammogram to examine a woman's breast for breast cancer.Hannibal Hanschke | dpa | Picture Alliance | Getty ImagesSAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead.That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco, the nation's largest gathering of biotech and pharmaceutical executives, analysts and investors. During the four-day event,…

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.Copyright ©2024 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8 Johnson & Johnson will acquire cancer-treatment developer AmbrxBiopharma in a $2 billion cash deal.The pharmaceutical giant said Monday that the…

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Mark Ralston | AFP | Getty ImagesJohnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment.Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as "guided missiles" to directly target and kill cancer cells and minimize damage to…